Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
- Conditions
- Ann Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular LymphomaGrade 3a Follicular Lymphoma
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04404088
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04404283
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - NAHOA, Goodyear, Arizona, United States
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 17
- Registration Number
- NCT04352205
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT04301076
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14
- Registration Number
- NCT04272775
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 337
- Registration Number
- NCT04270409
- Locations
- 🇦🇺
Investigational Site Number :0360008, Liverpool, New South Wales, Australia
🇯🇵Investigational Site Number :3920001, Shibuya-ku, Tokyo, Japan
🇱🇹Investigational Site Number :4400001, Vilnius, Lithuania
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 306
- Registration Number
- NCT04268498
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 237
- Registration Number
- NCT04246086
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Swedish Medical Center; IDS Pharmacy, Seattle, Washington, United States
🇨🇳the First Hospital of Jilin University, Changchun, China
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04231370
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 211
- Registration Number
- NCT04217967
- Locations
- 🇨🇳
PekingUMCH, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.